Stage-Specific Roles of Plasma GFAP in Linking Amyloid Cascade in Alzheimer Disease

INTRODUCTION: Astrocytic reactivity, measured by plasma glial fibrillary acidic protein (GFAP), is robustly elevated across the Alzheimer disease (AD) continuum, yet its relationship with the amyloid cascade remains poorly understood. METHODS: We integrated plasma GFAP with multimodal AD biomarkers, including cerebrospinal fluid (CSF) or plasma amyloid-beta (Abeta42/40), amyloid and tau positron emission tomography (PET), structural MRI, and clinical severity, across a discovery cohort (Knight Alzheimer Disease Research Center, n=278) and an independent replication cohort (Alzheimer's Disease

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.